Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

A prospective study of grey matter and cognitive function alterations in chemotherapy-treated breast cancer patients
Christian Lepage, Andra Smith, Jeremy T. Moreau, et al.
SpringerPlus (2014) Vol. 3, Iss. 1
Open Access | Times Cited: 94

Showing 1-25 of 94 citing articles:

Cancer-related cognitive impairment: an update on state of the art, detection, and management strategies in cancer survivors
Marie Lange, Florence Joly, Janette Vardy, et al.
Annals of Oncology (2019) Vol. 30, Iss. 12, pp. 1925-1940
Open Access | Times Cited: 484
Neurotoxic Effects of Anthracycline- vs Nonanthracycline-Based Chemotherapy on Cognition in Breast Cancer Survivors
Shelli R. Kesler, Douglas W. Blayney
JAMA Oncology (2015) Vol. 2, Iss. 2, pp. 185-185
Open Access | Times Cited: 148
Metformin Prevents Cisplatin-Induced Cognitive Impairment and Brain Damage in Mice
Wenjun Zhou, Annemieke Kavelaars, Cobi J. Heijnen
PLoS ONE (2016) Vol. 11, Iss. 3, pp. e0151890-e0151890
Open Access | Times Cited: 141
Cytokine‐mediated blood brain barrier disruption as a conduit for cancer/chemotherapy‐associated neurotoxicity and cognitive dysfunction
Hannah R. Wardill, Kimberley A. Mander, Ysabella Van Sebille, et al.
International Journal of Cancer (2016) Vol. 139, Iss. 12, pp. 2635-2645
Open Access | Times Cited: 139
Chemotherapy, cognitive impairment and hippocampal toxicity
Jörg Dietrich, Morgan Prust, Jochen Kaiser
Neuroscience (2015) Vol. 309, pp. 224-232
Closed Access | Times Cited: 133
Longitudinal assessment of chemotherapy-induced changes in brain and cognitive functioning: A systematic review
Mingmei Li, Karen Caeyenberghs
Neuroscience & Biobehavioral Reviews (2018) Vol. 92, pp. 304-317
Closed Access | Times Cited: 107
International Cognition and Cancer Task Force Recommendations for Neuroimaging Methods in the Study of Cognitive Impairment in Non-CNS Cancer Patients
Sabine Deprez, Shelli R. Kesler, Andrew J. Saykin, et al.
JNCI Journal of the National Cancer Institute (2017) Vol. 110, Iss. 3, pp. 223-231
Open Access | Times Cited: 84
Changes in cognitive functions and cerebral grey matter and their associations with inflammatory markers, endocrine markers, and APOE genotypes in testicular cancer patients undergoing treatment
Ali Amidi, Mads Agerbæk, Lisa M. Wu, et al.
Brain Imaging and Behavior (2016) Vol. 11, Iss. 3, pp. 769-783
Open Access | Times Cited: 80
Predicting Long-Term Cognitive Outcome Following Breast Cancer with Pre-Treatment Resting State fMRI and Random Forest Machine Learning
Shelli R. Kesler, Arvind Rao, Douglas W. Blayney, et al.
Frontiers in Human Neuroscience (2017) Vol. 11
Open Access | Times Cited: 79
Breast cancer treatment and its effects on aging
Leslie Chang, Lauren S Weiner, Sheri J. Hartman, et al.
Journal of Geriatric Oncology (2018) Vol. 10, Iss. 2, pp. 346-355
Open Access | Times Cited: 75
Disrupted brain network functional dynamics and hyper‐correlation of structural and functional connectome topology in patients with breast cancer prior to treatment
Shelli R. Kesler, Marjorie Adams, Melissa Packer, et al.
Brain and Behavior (2017) Vol. 7, Iss. 3
Open Access | Times Cited: 73
Recovery from chemotherapy-induced white matter changes in young breast cancer survivors?
Thibo Billiet, Louise Emsell, Mathieu Vandenbulcke, et al.
Brain Imaging and Behavior (2017) Vol. 12, Iss. 1, pp. 64-77
Closed Access | Times Cited: 65
Chemotherapy-induced brain changes in breast cancer survivors: evaluation with multimodality magnetic resonance imaging
Yun Feng, Xiao Dong Zhang, Gang Zheng, et al.
Brain Imaging and Behavior (2019) Vol. 13, Iss. 6, pp. 1799-1814
Closed Access | Times Cited: 59
Systematic review of cognitive sequelae of non-central nervous system cancer and cancer therapy
Noemí Cerulla, J. Blas Navarro, Núria de la Osa
Journal of Cancer Survivorship (2020) Vol. 14, Iss. 4, pp. 464-482
Closed Access | Times Cited: 54
Subtle hippocampal deformities in breast cancer survivors with reduced episodic memory and self-reported cognitive concerns
Alexandra C. Apple, Anthony J. Ryals, Kathryn I. Alpert, et al.
NeuroImage Clinical (2017) Vol. 14, pp. 685-691
Open Access | Times Cited: 53
Chemotherapy-induced cognitive impairments: A systematic review of the animal literature
A. Matsos, Ian N. Johnston
Neuroscience & Biobehavioral Reviews (2019) Vol. 102, pp. 382-399
Closed Access | Times Cited: 53
TFEB ameliorates the impairment of the autophagy-lysosome pathway in neurons induced by doxorubicin
Jose F. Moruno-Manchon, Ndidi-Ese Uzor, Shelli R. Kesler, et al.
Aging (2016) Vol. 8, Iss. 12, pp. 3507-3519
Open Access | Times Cited: 52
The Developmental Trajectory of Cancer-Related Cognitive Impairment in Breast Cancer Patients: A Systematic Review of Longitudinal Neuroimaging Studies
Helena Sousa, Susana Almeida, João M. Bessa, et al.
Neuropsychology Review (2020) Vol. 30, Iss. 3, pp. 287-309
Open Access | Times Cited: 46
Doxorubicin treatment has a biphasic effect over time on dopamine release and impulsive behavior in Wistar rats
Kiersten Jade Garcia, Jacob T. Theismann, Tadd D. Schneider, et al.
Naunyn-Schmiedeberg s Archives of Pharmacology (2025)
Closed Access
Peroxisomes contribute to oxidative stress in neurons during doxorubicin-based chemotherapy
Jose F. Moruno-Manchon, Ndidi-Ese Uzor, Shelli R. Kesler, et al.
Molecular and Cellular Neuroscience (2017) Vol. 86, pp. 65-71
Open Access | Times Cited: 47
Long-lasting impairments in adult neurogenesis, spatial learning and memory from a standard chemotherapy regimen used to treat breast cancer
Catarina Rendeiro, Andrew Sheriff, Tushar K. Bhattacharya, et al.
Behavioural Brain Research (2016) Vol. 315, pp. 10-22
Closed Access | Times Cited: 46
Assessing brain volume changes in older women with breast cancer receiving adjuvant chemotherapy: a brain magnetic resonance imaging pilot study
Bihong T. Chen, Sean K. Sethi, Taihao Jin, et al.
Breast Cancer Research (2018) Vol. 20, Iss. 1
Open Access | Times Cited: 38
Gray matter density reduction associated with adjuvant chemotherapy in older women with breast cancer
Bihong T. Chen, Taihao Jin, Sunita K. Patel, et al.
Breast Cancer Research and Treatment (2018) Vol. 172, Iss. 2, pp. 363-370
Open Access | Times Cited: 38
Brain gray matter reduction and premature brain aging after breast cancer chemotherapy: a longitudinal multicenter data pooling analysis
Michiel B. de Ruiter, Rachael Deardorff, Jeroen Blommaert, et al.
Brain Imaging and Behavior (2023) Vol. 17, Iss. 5, pp. 507-518
Closed Access | Times Cited: 12
Sustained attention abnormalities in breast cancer survivors with cognitive deficits post chemotherapy: An electrophysiological study
Julia W. Y. Kam, Colleen A. Brenner, Todd C. Handy, et al.
Clinical Neurophysiology (2015) Vol. 127, Iss. 1, pp. 369-378
Closed Access | Times Cited: 36
Page 1 - Next Page

Scroll to top